{"organizations": [], "uuid": "ed08a824f3453cab364a1f98b771912611f79083", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "article.wn.com", "main_image": "http://i.ytimg.com/vi/YgEOdUicvPI/0.jpg", "site_section": "http://rss.wn.com/English/keyword/politics", "section_title": "WN.com - Politics News", "url": "http://article.wn.com/view/2015/10/19/Pfizer_s_Inotuzumab_Ozogamicin_Receives_FDA_Breakthrough_The_k/", "country": "GB", "title": "Pfizer’s Inotuzumab Ozogamicin Receives FDA Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia (ALL) (Pfizer Inc) ...", "performance_score": 0, "site": "wn.com", "participants_count": 1, "title_full": "Pfizer’s Inotuzumab Ozogamicin Receives FDA Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia (ALL) (Pfizer Inc) ... - Worldnews.com", "spam_score": 0.0, "site_type": "news", "published": "2015-10-19T03:00:00.000+03:00", "replies_count": 0, "uuid": "ed08a824f3453cab364a1f98b771912611f79083"}, "author": "wn.com", "url": "http://article.wn.com/view/2015/10/19/Pfizer_s_Inotuzumab_Ozogamicin_Receives_FDA_Breakthrough_The_k/", "ord_in_thread": 0, "title": "Pfizer’s Inotuzumab Ozogamicin Receives FDA Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia (ALL) (Pfizer Inc) ...", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "( Source : Pfizer Inc ) NEW YORK--(BUSINESS WIRE )--Pfizer Inc. today announced that investigational antibody-drug conjugate ( ADC ) inotuzumab ozogamicin received Breakthrough Therapy designation from the U.S. Food and Drug Administration ( FDA )", "external_links": [], "published": "2015-10-19T03:00:00.000+03:00", "crawled": "2015-10-19T15:08:32.827+03:00", "highlightTitle": ""}